https://assets.capyfin.com/instruments/678fdc13234e27009c5d5a8a.png avatar
Zimmer Biomet
🇺🇸 NYSE:ZBH
View Company
OverviewEarningsDividends
•
Mar 31, 2024

Zimmer Biomet Q1 2024 Earnings Report

Reported an increase in net sales and adjusted diluted earnings per share in the first quarter of 2024 and reiterated full-year 2024 financial guidance.

Key Takeaways

Zimmer Biomet reported first quarter net sales of $1.889 billion, a 3.2% increase over the prior year, and a 4.4% increase on a constant currency basis. Diluted earnings per share were $0.84, and adjusted diluted earnings per share were $1.94. The company reiterated its full-year 2024 financial guidance.

First quarter net sales of $1.889 billion increased 3.2% and 4.4% on a constant currency basis.

First quarter diluted earnings per share were $0.84; adjusted diluted earnings per share were $1.94.

Company reiterates full-year 2024 financial guidance

Received FDA 510(k) clearance for the ROSA® Shoulder System and the Z1 Femoral Hip Stem.

Total Revenue
$1.89B
Previous year: $1.83B
+3.2%
EPS
$1.94
Previous year: $1.89
+2.6%
Gross Profit
$1.17B
Previous year: $1.33B
-12.1%
Cash and Equivalents
$393M
Previous year: $330M
+19.0%
Free Cash Flow
$173M
Previous year: $261M
-33.8%
Total Assets
$21.5B
Previous year: $21.2B
+1.0%

Zimmer Biomet

Zimmer Biomet

Zimmer Biomet Revenue by Segment

Forward Guidance

The Company is reiterating its current full-year 2024 financial guidance.

Positive Outlook

  • 2024 Reported Revenue Change 4.5% - 5.5%
  • 2024 Constant Currency Revenue Change 5.0% - 6.0%
  • Adjusted Diluted EPS $8.00 - $8.15

Challenges Ahead

  • Foreign Currency Exchange Impact (0.5)%

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Zimmer Biomet